STOCK TITAN

Harrow Inc - HROW STOCK NEWS

Welcome to our dedicated news page for Harrow (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harrow's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harrow's position in the market.

Rhea-AI Summary
Harrow (Nasdaq: HROW) Announces Participation in Upcoming Conferences, BTIG 3rd Annual Ophthalmology Day and Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) - Harrow, a leading U.S. eyecare pharmaceutical company, reported record revenues of $34.3 million in the third quarter of 2023, marking a 50% increase over the prior-year revenues. The company also announced a GAAP net loss of $(4.4 million) and an adjusted EBITDA of $9.2 million, representing a 270% increase over the prior-year quarter. Additionally, Harrow completed the transfer of NDAs and launched several products in the U.S., including FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE®. CEO Mark L. Baum commented on the results, highlighting the exceptional performance of the IHEEZO® launch and the substantial increase in unit demand in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.01%
Tags
-
Rhea-AI Summary
Harrow, a leading U.S. eyecare pharmaceutical company, will release its financial results for Q3 2023 on November 13, 2023. The company will also provide a business update during a conference call and live webcast at 4:45 p.m. Eastern Time. Participants can access the webcast on harrow.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
Rhea-AI Summary
Harrow has completed the transfer of New Drug Applications for several eyecare pharmaceutical products and has launched them in the U.S. market. The company aims to increase brand awareness and sales through its marketing and sales teams. Product orders can be made through Cardinal's Cordlogistics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) changes its corporate name to Harrow, Inc. to align with its strategic focus on eyecare pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary
Melt Pharmaceuticals enters exclusive development and license agreement with Catalent for MELT-300, a sublingual formulation for procedural sedation during cataract surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
Rhea-AI Summary
Harrow announces record revenues of $33.5 million, a 44% increase YoY, and a net loss of ($4.2) million. Also reports record adjusted EBITDA of $11.0 million, a 144% increase YoY. Completed public offering of common stock for $69 million. Acquired commercial rights to several drugs. Expanded Oaktree Loan to $112.50 million. Positive financial performance and acquisitions may positively impact stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.45%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.84%
Tags
Harrow Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

447.34M
26.55M
14.59%
66.11%
17.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Nashville

About HROW

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas